Patents Assigned to Micromedmark Biotech Co., Ltd.
-
Patent number: 11304970Abstract: Provided are an EGFR gene expression-suppressing siRNA, a precursor sequence of same, and uses thereof.Type: GrantFiled: May 5, 2017Date of Patent: April 19, 2022Assignee: JIANGSU MICROMEDMARK BIOTECH CO., LTD.Inventors: Chenyu Zhang, Xi Chen, Hongwei Liang, Uzair Ur-Rehman
-
Patent number: 10982213Abstract: The present invention discloses an siRNA that inhibits K-RAS gene expression, and the precursor sequences and applications thereof. The K-RAS siRNA and its precursor sequences provided by the present invention can efficiently inhibit the expression of the K-RAS gene, and in vivo experiments have shown that the K-RAS siRNA has a certain inhibitory effect on tumours highly expressing K-RAS. The precursor of the siRNA of the invention and its vector can form a stable siRNA that functions in a host.Type: GrantFiled: May 5, 2017Date of Patent: April 20, 2021Assignee: JIANGSU MICROMEDMARK BIOTECH CO., LTD.Inventors: Chenyu Zhang, Xi Chen, Hongwei Liang, Uzair Ur-Rehman, Ke Zeng
-
Patent number: 10774386Abstract: Provided are non-small cell lung cancer markers and the use thereof in diagnosing and monitoring diseases in vitro. The non-small cell lung cancer markers include at least one of 26 selected detectable mature microRNAs existing stably in human serum or plasma. Also provided are probe combinations, a kit and a biochip for detecting the non-small cell lung cancer markers. The invention further provides a method for detecting the said lung cancer markers. The method in the present invention enables extensive detection spectrum, high sensitivity, low cost, convenient sample taking and preservation. The method can be applied in the general survey of disease, solves problems of low specificity and sensitivity encountered with previous single markers, and increases significantly the clinical detection rate of diseases. The methods provide an effective means for diagnosing diseases at an early stage.Type: GrantFiled: July 11, 2016Date of Patent: September 15, 2020Assignee: MICROMEDMARK BIOTECH CO., LTD.Inventors: Chenyu Zhang, Ke Zeng, Junfeng Zhang, Yi Ba, Xi Chen, Haijin Li
-
Patent number: 10533173Abstract: Provided are a new precursor miRNA and the applications in tumor therapy thereof. The precursor miRNA, from 5?- to 3?-end thereof, has the structure represented by formula (I). B1 is an anti-miRNA and/or siRNA to be expressed; B2 is a sequence substantially or completely complementary to B1, and B2 is not complementary to C; C is a sequence with stem-loop structure; A1 and A2 are independently hydrogen or optionally a RNA sequence consisting of 4 to 5 bases. The precursor miRNA can be processed to form an anti-miRNA and/or siRNA in hosts.Type: GrantFiled: May 5, 2016Date of Patent: January 14, 2020Assignee: JIANGSU MICROMEDMARK BIOTECH CO., LTD.Inventors: Chenyu Zhang, Ke Zeng, Xi Chen, Junfeng Zhang, Hongwei Liang
-
Patent number: 10519441Abstract: Provided is a use of miRNA-214 inhibitor in inhibiting regulatory T cells (Treg cells). The microRNA-214 (miRNA-214) can promote Treg cells, and can assist tumors in immune escape. The experiments demonstrates that the inhibition of miRNA-214 can inhibit the growth of Treg cells, thus inhibiting the growth of tumors. Therefore, miRNA-214 can be used for developing an anti-tumour drug or a drug inhibiting immune response hyperactivity.Type: GrantFiled: December 18, 2014Date of Patent: December 31, 2019Assignee: Jiangsu Micromedmark Biotech Co., Ltd.Inventors: Chenyu Zhang, Ke Zeng, Yuan Yin, Xing Cai, Junfeng Zhang
-
Publication number: 20190382769Abstract: The present invention discloses an siRNA that inhibits K-RAS gene expression, and the precursor sequences and applications thereof. The K-RAS siRNA and its precursor sequences provided by the present invention can efficiently inhibit the expression of the K-RAS gene, and in vivo experiments have shown that the K-RAS siRNA has a certain inhibitory effect on tumours highly expressing K-RAS. The precursor of the siRNA of the invention and its vector can form a stable siRNA that functions in a host.Type: ApplicationFiled: May 5, 2017Publication date: December 19, 2019Applicant: JIANGSU MICROMEDMARK BIOTECH CO., LTD.Inventors: Chenyu ZHANG, Xi CHEN, Hongwei LIANG, Uzair UR-REHMAN, Ke ZENG
-
Publication number: 20190255090Abstract: Provided are an EGFR gene expression-suppressing siRNA, a precursor sequence of same, and uses thereof.Type: ApplicationFiled: May 5, 2017Publication date: August 22, 2019Applicant: JIANGSU MICROMEDMARK BIOTECH CO., LTD.Inventors: Chenyu ZHANG, Xi CHEN, Hongwei LIANG, Uzair UR-REHMAN
-
Patent number: 10308932Abstract: The present invention relates to a microparticle comprising a functional microRNA/siRNA and application thereof. Specifically, disclosed is a use of a functional microRNA and/or siRNA, which is used to prepare a composition applied to a mammal. After the composition is applied, the microparticle is formed in a first part in an animal, and transported to a second part, which thereby improves physiological status of the second part or heals a disease of the second part. The second part is different from the first part. The use is beneficial for optimizing a dosing manner of the functional microRNA and/or siRNA.Type: GrantFiled: June 21, 2013Date of Patent: June 4, 2019Assignee: MICROMEDMARK BIOTECH CO., LTD.Inventors: Chenyu Zhang, Ke Zeng
-
Patent number: 10240150Abstract: The present invention relates to an avian influenza virus miRNA and the identification, detection and application thereof. In particular, a kind of specific microRNA, miR-HA-3p, is screened for the first time through detecting the microRNA expression levels in samples of animals with avian influenza. The experiments prove that the miR-HA-3p, as a microRNA marker, can be very effective in detecting avian influenza virus and avian influenza. Furthermore, inhibiting the function of miR-HA-3p can be very effective in relieving symptoms of avian influenza and treating avian influenza. The microRNA revealed in the present invention for the first time can be developed into a detection agent and a therapeutic agent as well as the corresponding kits for the detection and treatment of avian influenza (e.g., H5N1).Type: GrantFiled: December 9, 2014Date of Patent: March 26, 2019Assignee: JIANGSU MICROMEDMARK BIOTECH CO., LTD.Inventors: Chenyu Zhang, Ke Zeng, Jin Wang, Xihan Li
-
Plants as functional microRNA and/or functional siRNA carriers, preparation methods and uses thereof
Patent number: 10227603Abstract: The invention relates to plants as functional microRNA and/or functional siRNA vehicles, the preparation methods and uses thereof. In particular, disclosed in the present invention are plants or edible portions or extracts thereof as functional microRNA and/or functional siRNA vehicles and uses thereof. Also disclosed is a method for carrying the functional microRNA and/or functional siRNA, comprising the step of orally administering the plants or edible portions or extracts thereof to a subject in need thereof, wherein the plants or edible portions thereof express and carry the functional microRNA and/or functional siRNA vehicles, and the extracts contain the functional microRNA and/or functional siRNA.Type: GrantFiled: May 15, 2013Date of Patent: March 12, 2019Assignee: MICROMEDMARK BIOTECH CO., LTD.Inventors: Chenyu Zhang, Zhi Hong, Ke Zeng -
Patent number: 10155947Abstract: Provided are a method and use of microRNA MiR-2911 in regulating an ebola virus. Particularly provided are a method and use of isolated microRNA MiR-2911 in regulating an ebola virus protein gene.Type: GrantFiled: September 1, 2015Date of Patent: December 18, 2018Assignee: JIANGSU MICROMEDMARK BIOTECH CO., LTD.Inventors: Chenyu Zhang, Hongwei Liang, Zhen Zhou, Ke Zeng, Xi Chen
-
Publication number: 20180223277Abstract: Provided are a new precursor miRNA and the applications in tumor therapy thereof. The precursor miRNA, from 5?- to 3?-end thereof, has the structure represented by formula (I). B1 is an anti-miRNA and/or siRNA to be expressed; B2 is a sequence substantially or completely complementary to B1, and B2 is not complementary to C; C is a sequence with stem-loop structure; A1 and A2 are independently hydrogen or optionally a RNA sequence consisting of 4 to 5 bases. The precursor miRNA can be processed to form an anti-miRNA and/or siRNA in hosts.Type: ApplicationFiled: May 5, 2016Publication date: August 9, 2018Applicant: JIANGSU MICROMEDMARK BIOTECH CO., LTD.Inventors: Chenyu ZHANG, Ke ZENG, Xi CHEN, Junfeng ZHANG, Hongwei LIANG
-
Patent number: 9909127Abstract: Provided is non-coded RNA of in-vivo infected microorganisms, parasitic microorganisms, symbiotic microorganisms and identification and application thereof. Also provided is a method of identifying the non-coded RNA of in-vivo pathogen sources. The invention also provided a pharmaceutical composition containing an inhibitor for specifically inhibiting or blocking a RNA sequence and a method to treat a pathogen infectious disease or parasitic disease by administering an inhibitor, which inhibits a non-coding RNA sequence derived from a pathogen in the body of an animal, to an animal subject in need thereof.Type: GrantFiled: December 9, 2014Date of Patent: March 6, 2018Assignee: JIANGSU MICROMEDMARK BIOTECH CO., LTD.Inventors: Chenyu Zhang, Ke Zeng, Jin Wang, Xihan Li, Hongwei Gu
-
Patent number: 9903002Abstract: The present invention provides Salmonella non-coding RNA and the identification and application thereof. In particular, the present invention proves through experiments that a Salmonella bacterium delivers non-coding RNAs (ncRNAs) encoded by the bacterium itself into a host cell, generates milRNAs similar to microRNAs by means of a microRNA splicing system in the cell, regulates the immune system with the milRNAs, and further protects the Salmonella bacterium from being cleared by the host. Adsorbing milRNAs using milRNA inhibitors can effectively inhibit the survival ability of the bacterium in the cell, leading to a reduced vitality of the bacterium. The present invention further provides relevant reagents and methods for effective detection of, treatment to and study on Salmonella bacteria or Salmonella infectious diseases.Type: GrantFiled: December 9, 2014Date of Patent: February 27, 2018Assignee: JIANGSU MICROMEDMARK BIOTECH CO., LTD.Inventors: Ke Zeng, Hongwei Gu, Chenyu Zhang, Tianfu Zhang
-
Patent number: 9752148Abstract: An isolated plant-functional microRNA or an extract containing said plant-functional microRNA, a preparation method therefor, and an application thereof are provided. The plant-functional microRNA originates from the endogenous microRNA of a plant, is present in a water-soluble and/or fat-soluble extract of said plant, and is capable of regulating non-plant target-genes.Type: GrantFiled: August 15, 2013Date of Patent: September 5, 2017Assignee: Micromedmark Biotech Co., Ltd.Inventors: Chenyu Zhang, Junfeng Zhang, Ke Zeng, Lei Dong
-
Patent number: 9637793Abstract: The present invention provides microRNAs for assessing the status of pancreatic cancer in a subject, and provides methods, kits, and biochips for detecting said microRNAs.Type: GrantFiled: December 24, 2009Date of Patent: May 2, 2017Assignee: Micromedmark Biotech Co., Ltd.Inventors: Chenyu Zhang, Rui Liu, Cheng Wang, Yi Bai, Chunni Zhang, Ke Zeng
-
Publication number: 20170044549Abstract: Provided is an siRNA in tandem expression and uses thereof in treating chronic lymphocytic leukemia, and particularly, provided are a method of a tandem expression for siRNA of BTK, and an siRNA in tandem expression and uses thereof in treating chronic lymphocytic leukemia.Type: ApplicationFiled: January 29, 2015Publication date: February 16, 2017Applicant: Jiangsu Micromedmark Biotech Co., LTD.Inventors: Chenyu Zhang, Ke Zeng, Hongwei Gu, Xueliang Wang
-
Publication number: 20160319332Abstract: The present invention provides Salmonella non-coding RNA and the identification and application thereof. In particular, the present invention proves through experiments that a Salmonella bacterium delivers non-coding RNAs (ncRNAs) encoded by the bacterium itself into a host cell, generates milRNAs similar to microRNAs by means of a microRNA splicing system in the cell, regulates the immune system with the milRNAs, and further protects the Salmonella bacterium from being cleared by the host. Adsorbing milRNAs using milRNA inhibitors can effectively inhibit the survival ability of the bacterium in the cell, leading to a reduced vitality of the bacterium. The present invention further provides relevant reagents and methods for effective detection of, treatment to and study on Salmonella bacteria or Salmonella infectious diseases.Type: ApplicationFiled: December 9, 2014Publication date: November 3, 2016Applicant: JIANGSU MICROMEDMARK BIOTECH CO. LTD.Inventors: Ke ZENG, Hongwei GU, Chenyu ZHANG, Tianfu ZHANG
-
Publication number: 20160312221Abstract: Provided is non-coded RNA of in-vivo infected microorganisms, parasitic microorganisms, symbiotic microorganisms and identification and application thereof. Also provided is a method of identifying the non-coded RNA of in-vivo pathogen sources.Type: ApplicationFiled: December 9, 2014Publication date: October 27, 2016Applicant: JIANGSU MICROMEDMARK BIOTECH CO., LTD.Inventors: Chenyu ZHANG, Ke ZENG, Jin WANG, Xihan LI, Hongwei GU
-
Patent number: 9428808Abstract: This invention provides markers, methods, biochips and kits for milk quality detection. The present invention particularly provides a method for milk quality detection by means of detecting the particular microRNAs in milk, so as to establish the standard of raw milk content.Type: GrantFiled: May 27, 2010Date of Patent: August 30, 2016Assignee: JIANGSU MICROMEDMARK BIOTECH CO., LTD.Inventors: Chengyu Zhang, Ke Zeng, Junfeng Zhang, Chunliang Tian, Haijin Li